Viewing Study NCT05198960

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:02 AM
Ignite Modification Date: 2026-07-07 @ 10:12 AM
Study NCT ID: NCT05198960
Status: RECRUITING
Last Update Posted: 2025-02-04
First Post: 2021-11-09
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Sponsor: University Hospital, Brest
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Polycythemia Vera View
None Essential Thrombocythemia View
None Prefibrotic/Early Primary Myelofibrosis View
None JAK2 V617F View
None High-risk Patients View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Venous ThromboEmbolism View
None Arterial Thrombosis View
None Hemorrhage View